Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company developing FcRn-targeting monoclonal antibodies for IgG-mediated autoimmune diseases. The news flow around IMVT reflects its focus on advancing its lead asset IMVT-1402 and its first-generation antibody batoclimab through multiple clinical programs and financing events.
On this page, readers can follow company-issued updates such as quarterly and annual financial results, where Immunovant reports research and development spending, general and administrative expenses, net loss and cash position. These releases often include details on the status of potentially registrational trials of IMVT-1402 in Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus.
News items also cover clinical data readouts. Immunovant has announced topline results from a Phase 3 study of batoclimab in myasthenia gravis and initial results from a Phase 2b study in CIDP, highlighting correlations between deeper IgG reductions and improved clinical outcomes. Additional communications describe six‑month off‑treatment remission data from a batoclimab proof‑of‑concept study in uncontrolled Graves’ disease and the design of IMVT‑1402 trials informed by these findings.
Investors can also see coverage of corporate developments, including leadership transitions, changes in board composition and strategic alignment with controlling stockholder Roivant Sciences Ltd. Capital markets updates, such as the pricing of a common stock financing with anticipated gross proceeds of approximately $550 million, are reported through news releases as well.
For anyone tracking IMVT, this news feed provides company-sourced information on clinical milestones, financial reporting, governance changes and equity offerings related to Immunovant’s autoimmune disease pipeline.
Immunovant is hosting a virtual R&D event on March 30, 2022, showcasing discussions on therapies for autoimmune diseases like thyroid eye disease and myasthenia gravis. The event will feature six key opinion leaders in these fields, focusing on the treatment landscape and the potential of batoclimab (IMVT-1401) to meet patient needs. New analyses from the Phase 2b study on thyroid eye disease and a Phase 1 study on batoclimab and atorvastatin will be presented, followed by a live Q&A with company management.
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. The chat is scheduled for February 16 at 11:20 AM ET. Investors can access the webcast via the Investor Relations section of Immunovant's website. The company focuses on developing batoclimab, a monoclonal antibody aimed at treating autoimmune diseases driven by pathogenic IgG antibodies.
Immunovant (Nasdaq: IMVT) reported its fiscal Q1 2022 results, ending December 31, 2021, with approximately $527 million in cash. R&D expenses rose to $29.8 million from $21.1 million in Q1 2021, driven by cross-indication clinical studies and personnel costs. General and administrative expenses increased to $11.5 million from $10.5 million. The net loss widened to $41.4 million ($0.36 per share), compared to $31.8 million ($0.32 per share) a year earlier. The nine-month net loss reached $109.6 million.
Immunovant has appointed Mark Levine as Chief Legal Officer, bringing over 20 years of legal experience in biopharmaceuticals. His expertise includes overseeing mergers and guiding regulatory compliance. As the company accelerates the development of its drug batoclimab, Levine's addition is expected to enhance strategic capabilities. Notably, Immunovant plans to initiate three pivotal trials for batoclimab in 2022, focusing on myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia, among others.
Immunovant, Inc. (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:45 AM Eastern Time. The conference will showcase the company's focus on autoimmune diseases and the development of IMVT-1401 (batoclimab), a novel treatment aimed at managing conditions linked to pathogenic IgG antibodies. The presentation will be available via webcast on the company’s website.
Immunovant, Inc. (Nasdaq: IMVT) has aligned with the FDA to advance its Phase 3 trial for batoclimab, targeting myasthenia gravis (MG). Set to commence in the first half of 2022, the trial will investigate doses of 680mg and 340mg through subcutaneous injection, focusing on the MG-ADL primary efficacy measure. The trial aims to explore its broad therapeutic window and patient-friendly dosing. Results are expected in 2024, with further details to be discussed in an investor call on January 5, 2022.
On November 12, 2021, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate overview at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. The presentation is scheduled for November 17 at 2:00 PM ET and will be accessible via webcast on the company’s website. Immunovant is focused on developing IMVT-1401 (batoclimab), a monoclonal antibody aimed at treating autoimmune diseases mediated by IgG antibodies.
Immunovant (Nasdaq: IMVT) reported its fiscal first-quarter results for the period ending September 30, 2021. The company ended the quarter with approximately $559 million in cash. R&D expenses rose to $21.4 million, up from $12.0 million year-over-year, primarily due to higher contract manufacturing and personnel costs. G&A expenses also increased to $16.3 million, compared to $9.0 million last year. The net loss for the quarter was $37.7 million ($0.35 per share), compared to a loss of $20.8 million ($0.25 per share) in the same quarter of 2020.
Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company specializing in autoimmune diseases, announced participation by CEO Pete Salzmann, M.D. in a fireside chat at Roivant R&D Day 2021 on September 28, 2021, at 4:00 p.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days afterwards on the company's investor page. Immunovant is advancing IMVT-1401, an innovative treatment targeting diseases caused by harmful IgG antibodies.
Immunovant appoints Renee Barnett as Chief Financial Officer effective October 4, 2021, enhancing its executive leadership team. Ms. Barnett brings over 20 years of financial expertise in healthcare, having worked at Eli Lilly and most recently at AbleTo, Inc. Her appointment comes as Immunovant prepares to initiate pivotal trials for batoclimab (IMVT-1401) in multiple indications, including myasthenia gravis, and reinitiate programs for thyroid eye disease and warm autoimmune hemolytic anemia.